850
PATIENTS WITH MAFLD TAKING GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT HAVE HIGHER INCIDENCE FOR HEPATOBILIARY CANCER BUT HAVE LOWER OVERALL MORTALITY: A MULTI-CENTER ANALYSIS.
Date
May 20, 2024
Tracks
Related Products
BARIATRIC SURGERY OUTCOMES AND VOLUMES DURING THE EARLY COVID 19 PANDEMIC
BACKGROUND: To address the persistent ethnoracial and socioeconomic disparities in access to quality surgical cancer care, it is imperative to rigorously understand the role of clinician-level factors including clinician-to-clinician connectedness…
GLUCAGON LIKE PEPTIDE-1 (GLP-1) AGONISTS USE IS NOT ASSOCIATED WITH WORSE OUTCOMES OR INCREASED MORTALITY POST ENDOSCOPY: A MULTI-CENTER ANALYSIS
Glucagon Like Peptide-1 (GLP-1) agonists exert their effect by inhibiting postprandial glucagon secretion, promoting glucose-dependent insulin secretion and mitigating food consumption by delaying gastric emptying…
PATIENTS ADMITTED WITH ACUTE CHOLECYSTITIS AND ASSOCIATED COVID 19 HAD LESS RATES OF SAME ADMISSION CHOLECYSTECTOMY BUT NOT INCREASED MORTALITY
BACKGROUND: The majority of HCC patients within Milan criteria, compete with cirrhosis patients with high MELD for liver transplantation based on an exceptional score which is the calculated MELD at registration, 28 after six months of waiting, 31 after 1 year and thereafter capped at 34 after one…